Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, Waldemar Falcão 121, CEP 40296-710, Salvador, Bahia, Brazil.
Toxicon. 2012 Nov;60(6):1005-12. doi: 10.1016/j.toxicon.2012.07.003. Epub 2012 Jul 24.
The therapeutic potential of snake venoms for pain control has been previously demonstrated. In the present study, the antinociceptive effects of Micrurus lemniscatus venom (MlV) were investigated in experimental models of pain. The antinociceptive activity of MIV was evaluated using the writhing, formalin, and tail flick tests. Mice motor performance was assessed in the rota rod and open field tests. In a screening test for new antinociceptive substances--the writhing test--oral administration of MlV (19.7-1600 μg/kg) produced significant antinociceptive effect. The venom (1600 μg/kg) also inhibited both phases of the formalin test, confirming the antinociceptive activity. The administration of MlV (1600 μg/kg) did not cause motor impairment in the rota rod and open field tests, which excluded possible non-specific muscle relaxant or sedative effects of the venom. The MIV (177-1600 μg/kg) also increases the tail flick latency response, indicating a central antinociceptive effect for the venom. In this test, the MlV-induced antinociceptive effect was long-lasting and higher than that of morphine, an analgesic considered the gold standard. In another set of experiments, the mechanisms involved in the venom-induced antinociception were investigated through the use of pharmacological antagonists. The MlV (1600 μg/kg) antinociceptive effect was prevented by naloxone (5 mg/kg), a non-selective opioid receptor antagonist, suggesting that this effect is mediated by activation of opioid receptors. In addition, the pre-treatment with the μ-opioid receptor antagonist CTOP (1 mg/kg) blocked the venom antinociceptive effect, while the k-opioid receptor antagonist nor-BNI (0.5 mg/kg) or the δ-opioid receptor antagonist naltrindole (3 mg/kg) only partially reduced the venom-induced antinociception. The present study demonstrates, for the first time, that oral administration of M. lemniscatus venom, at doses that did not induce any motor performance alteration, produced potent and long-lasting antinociceptive effect mediated by activation of opioid receptors.
蛇毒在控制疼痛方面的治疗潜力此前已得到证实。在本研究中,研究了矛头蝮蛇毒(MlV)在疼痛实验模型中的镇痛作用。使用扭体、福尔马林和尾部闪烁测试评估 MIV 的镇痛活性。在转棒和旷场测试中评估小鼠的运动表现。在新的镇痛物质筛选测试——扭体测试中——MlV(19.7-1600μg/kg)的口服给药产生了显著的镇痛作用。毒液(1600μg/kg)也抑制了福尔马林测试的两个阶段,证实了镇痛活性。MlV(1600μg/kg)的给药不会引起转棒和旷场测试中的运动障碍,这排除了毒液可能的非特异性肌肉松弛或镇静作用。MlV(177-1600μg/kg)还增加了尾部闪烁潜伏期反应,表明毒液具有中枢镇痛作用。在该测试中,MlV 诱导的镇痛作用持续时间长且高于作为金标准的镇痛剂吗啡。在另一组实验中,通过使用药理学拮抗剂研究了毒液诱导的镇痛作用涉及的机制。MlV(1600μg/kg)的镇痛作用被纳洛酮(5mg/kg)阻止,纳洛酮是非选择性阿片受体拮抗剂,表明这种作用是通过激活阿片受体介导的。此外,预先给予 μ-阿片受体拮抗剂 CTOP(1mg/kg)阻断了毒液的镇痛作用,而 k-阿片受体拮抗剂 nor-BNI(0.5mg/kg)或 δ-阿片受体拮抗剂naltrindole(3mg/kg)仅部分减少了毒液引起的镇痛作用。本研究首次表明,矛头蝮蛇毒的口服给药,在不引起任何运动表现改变的剂量下,产生了通过激活阿片受体介导的有效且持久的镇痛作用。